Jump to content

Globo H

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 14:11, 8 August 2022 (Alter: journal. | Use this bot. Report bugs. | Suggested by Abductive | #UCB_webform 705/3849). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Globo H
Names
IUPAC name
N-((2S,3R,E)-1-(((2R,3R,4R,5S,6R)-5-(((2S,3R,4R,5R,6R)-5-(((2R,3R,4S,5S,6R)-4-(((2S,3R,4R,5R,6R)-3-acetamido-4-(((2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-hydroxyoctadec-4-en-2-yl)palmitamide
Other names
  • globohexaosylceramide
  • α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→3)-α-D-Gal-(1→4)-β-D-Gal-(1→4)-α-D-GlcOCeramide
Identifiers
3D model (JSmol)
ChEBI
  • InChI=1S/C72H130N2O32/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-42(81)41(74-48(82)32-30-28-26-24-22-20-18-16-14-12-10-8-6-2)38-95-68-59(92)56(89)62(46(36-78)100-68)102-70-60(93)57(90)63(47(37-79)101-70)103-71-61(94)65(53(86)45(35-77)98-71)105-67-49(73-40(4)80)64(52(85)44(34-76)97-67)104-72-66(55(88)51(84)43(33-75)99-72)106-69-58(91)54(87)50(83)39(3)96-69/h29,31,39,41-47,49-72,75-79,81,83-94H,5-28,30,32-38H2,1-4H3,(H,73,80)(H,74,82)/b31-29+/t39-,41-,42+,43+,44+,45+,46+,47+,49+,50+,51-,52+,53-,54+,55-,56+,57+,58-,59+,60+,61+,62+,63-,64+,65-,66+,67-,68+,69-,70-,71+,72-/m0/s1
    Key: NQUSQNBGWFMOFP-PBNVMRQJSA-N
  • CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@H]3O[C@H](CO)[C@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@H](O)[C@H]5O[C@@H]5O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]5O)[C@H]4NC(C)=O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)NC(CCCCCCCCCCCCCCC)=O
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Globo H (globohexaosylceramide) is a globo-series glycosphingolipid antigen that is present on the outer membrane of some cancer cells.[1][2] Globo H is not expressed in normal tissue cells, but is expressed in a number of types of cancers, including cancers of the breast, prostate, and pancreas.[1][3] Globo H’s exclusivity for cancer cells makes it a target of interest for cancer therapies.[1][2]

Structure

Chemical Structure of Globo H[4]

Defined by the monoclonal antibody MBr1, Globo H has been isolated from breast cancer cell line MCF-7, and its structure has been determined through several analyses, including NMR spectroscopy and methylation analysis.[5] Globo H consists of a hexasaccharide of the structure Fucα(1-2)Galβ(1-3)GalNAcβ(1-3)Galα(1-4)Galβ(1-4)Glcβ(1) with a ceramide attached to its terminal glucose ring at the 1 position in a beta linkage.[6]

Synthesis

Biosynthesis

Biosynthesis of Globo H[1][7]

Globo H’s biosynthetic pathway is involved in the synthesis pathways of other globo-series glycosphingolipid antigens that are also specific to cancer cells, including stage-specific embryonic antigen-3 (SSEA3) and stage-specific embryonic antigen-4 (SSEA4).[1] The biosynthetic pathway of these antigens includes the enzyme β 1,3-galactosyltransferase V (β3GalT5).[1] β3GalT5 catalyzes the galactosylation of globoside-4 (Gb4) to SSEA3.[1] SSEA3 can then be converted to SSEA4 by sialyltransferase adding a sialic acid group to its end, or it can be converted to Globo H by fucosyltransferase adding a fucose ring to its end.[1] Playing a part in the formation of three different cancer-specific antigens, β3GalT5 is of particular interest in its relevance to cancer treatment, and it has been shown to be critical for cancer cell survival.[8]

Chemical Synthesis

In order to study its potential as a cancer therapy target, Globo H has been synthesized in the laboratory.[9] One synthesis is achieved by first building two trisaccharides from their component sugars, and then linking them.[9] The trisaccharides, with most of their functional groups protected to prevent side reactions, are linked by creating the GalNAcβ(1-3)Gal bond.[9] A thioethyl group is added to the 1 position on one of the protected galactose rings, and in the presence of methyl triflate, this reacts with the hydroxyl group on the 3 position of the other galactose to link the trisaccharides and form the hexasaccharide.[9] The ceramide is added to the 1 position of the terminal glucose ring after hexasaccharide formation.[9]

Globo H as a Therapeutic Target

As a Tumor Associated Carbohydrate Antigen (TACA), Globo-H is a promising clinical target for immunotherapy. While absent in normal tissues, the glycosphingolipid is overexpressed in a variety of epithelial cancer cell types including human pancreatic, gastric, lung, colorectal, esophageal, and breast tumors.[10][11]

Globo H Anticancer Vaccines

Globo-H’s TACA character allows for its utilization as an anticancer vaccine, inducing antibody response against the epitope. The resulting humoral immunity could enable the selective eradication of Globo H-presenting tumors.[12] The Taiwanese biopharma company OBI Pharma, Inc., was first to develop Adagloxad Simolenin (OBI-822), a Globo H hexasaccharide conjugated with the immunostimulatory carrier protein KLH.[12] The Phase III GLORIA study is underway evaluating the carbohydrate-based immunogen’s effects in high risk triple-negative breast cancer (TNBC) patients with an estimated completion date in 2027.[13]

Alternative vaccine conjugates have been developed which avoid issues associated with the protein carrier KLH by substituting it with a lipid or carbohydrate-based carrier. Examples include the use of lipid A derivatives[14] or entirely carbohydrate vaccine conjugates such as Globo H-PS A1[15]

Anti-Globo H Antibodies

Globo H-targeting antibodies are another strategy currently being evaluated in the cancer therapeutic space. OBI Pharma’s OBI-888 is a humanized IgG1 antibody that selectively binds to the Globo H antigen among other Globo series glycosphingolipids such as SSEA-3 and SSEA-4.[16] Additionally, in vivo studies of OBI-888 in various Globo H-positive (GH+) xenografts models showed promising tumor growth inhibition results.[17] OBI-888’s human Phase I/II study for the treatment of metastatic and locally advanced solid tumors is estimated to finish in December 2022.[18]

Based on OBI-888, the first-in-class antibody-drug conjugate (ADC) 0BI-999 was additionally developed, linking OBI-888 to monomethyl auristatin E, a synthetic antineoplastic agent.[19] The ADC is currently undergoing phase II trial in patients with advanced solid tumors, with an estimated completion date in Dec 2023.[20] In Dec 2019 & Jan 2020, OBI-999 was granted two Orphan Drug Designations by the FDA for the treatment of pancreatic and gastric cancer.[21]

References

  1. ^ a b c d e f g h Chuang, Po-Kai; Hsiao, Michael; Hsu, Tsui-Ling; Chang, Chuan-Fa; Wu, Chung-Yi; Chen, Bo-Rui; Huang, Han-Wen; Liao, Kuo-Shiang; Chen, Chen-Chun; Chen, Chi-Long; Yang, Shun-Min (2019-02-26). "Signaling pathway of globo-series glycosphingolipids and β1,3-galactosyltransferase V (β3GalT5) in breast cancer". Proceedings of the National Academy of Sciences. 116 (9): 3518–3523. doi:10.1073/pnas.1816946116. ISSN 0027-8424. PMC 6397564. PMID 30808745.
  2. ^ a b Hung, Jung-Tung; Cheng, Jing-Yan; Wu, Chia-Cheng; Yu, Alice L. (2012-04-15). "Abstract 2529: A monoclonal anti-Globo H antibody, VK9 can mediate CDC/ADCC and inhibit adhesion of Globo H+cancer cells to extracellular matrix". Abstract 2529: A monoclonal anti-Globo H antibody, VK9 can mediate CDC/ADCC and inhibit adhesion of Globo H+ cancer cells to extracellular matrix. Vol. 72. p. 2529. doi:10.1158/1538-7445.AM2012-2529. ISSN 0008-5472. {{cite book}}: |journal= ignored (help)
  3. ^ Yang, Ching-Yao; Lin, Mong-Wei; Chang, Yih-Leong; Wu, Chen-Tu (2017-12-12). "Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer". Cancer Biomarkers. 21 (1): 211–220. doi:10.3233/CBM-170660. ISSN 1875-8592. PMID 29036791.
  4. ^ Park, Tae Kyo; Kim, In Jong; Hu, Shuanghua; Bilodeau, Mark T.; Randolph, John T.; Kwon, Ohyun; Danishefsky, Samuel J. (1996-11-20). "Total Synthesis and Proof of Structure of a Human Breast Tumor (Globo-H) Antigen". Journal of the American Chemical Society. 118 (46): 11488–11500. doi:10.1021/ja962048b. ISSN 0002-7863.
  5. ^ Bremer, E. G.; Levery, S. B.; Sonnino, S.; Ghidoni, R.; Canevari, S.; Kannagi, R.; Hakomori, S. (1984-12-10). "Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland". The Journal of Biological Chemistry. 259 (23): 14773–14777. doi:10.1016/S0021-9258(17)42669-X. ISSN 0021-9258. PMID 6501317.
  6. ^ Wang, Cheng-Chi; Huang, Yen-Lin; Ren, Chien-Tai; Lin, Chin-Wei; Hung, Jung-Tung; Yu, Jyh-Cherng; Yu, Alice L.; Wu, Chung-Yi; Wong, Chi-Huey (2008-08-19). "Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer". Proceedings of the National Academy of Sciences. 105 (33): 11661–11666. Bibcode:2008PNAS..10511661W. doi:10.1073/pnas.0804923105. ISSN 0027-8424. PMC 2575271. PMID 18689688.
  7. ^ Detzner, Johanna; Pohlentz, Gottfried; Müthing, Johannes (2020-06-04). "Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome". Toxins. 12 (6): 373. doi:10.3390/toxins12060373. ISSN 2072-6651. PMC 7354503. PMID 32512916.
  8. ^ Cheung, Sarah K. C.; Chuang, Po-Kai; Huang, Han-Wen; Hwang-Verslues, Wendy W.; Cho, Candy Hsin-Hua; Yang, Wen-Bin; Shen, Chia-Ning; Hsiao, Michael; Hsu, Tsui-Ling; Chang, Chuan-Fa; Wong, Chi-Huey (2015-12-17). "Stage-specific embryonic antigen-3 (SSEA-3) and β3GalT5 are cancer specific and significant markers for breast cancer stem cells". Proceedings of the National Academy of Sciences. 113 (4): 960–965. doi:10.1073/pnas.1522602113. ISSN 0027-8424. PMC 4743801. PMID 26677875.
  9. ^ a b c d e Bilodeau, Mark T.; Park, Tae Kyo; Hu, Shuanghua; Randolph, John T.; Danishefsky, Samuel J.; Livingston, Philip O.; Zhang, Shengli (1995-07-01). "Total Synthesis of a Human Breast Tumor Associated Antigen". Journal of the American Chemical Society. 117 (29): 7840–7841. doi:10.1021/ja00134a043. ISSN 0002-7863.
  10. ^ Zhang, Shengle; Cordon-Cardo, Carlos; Zhang, Helen S.; Reuter, Victor E.; Adluri, Sucharita; Hamilton, Wm. Bradley; Lloyd, Kenneth O.; Livingston, Philip O. (1997-09-26). <42::aid-ijc8>3.0.co;2-1 "Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides". International Journal of Cancer. 73 (1): 42–49. doi:10.1002/(sici)1097-0215(19970926)73:1<42::aid-ijc8>3.0.co;2-1. ISSN 0020-7136. PMID 9334808. S2CID 22303340.
  11. ^ Chen, I-Ju; Yang, Ming-Chen; Chen, Yu-Jung (2020-08-13). "Abstract 2946: The prevalence of Globo H in different tumor types: Breast, pancreatic, lung, gastric, colorectal, liver, and esophageal cancers". Experimental and Molecular Therapeutics. Vol. 80. American Association for Cancer Research. p. 2946. doi:10.1158/1538-7445.am2020-2946. S2CID 225447790. {{cite book}}: |journal= ignored (help)
  12. ^ a b Danishefsky, Samuel J.; Shue, Youe-Kong; Chang, Michael N.; Wong, Chi-Huey (2015-03-17). "Development of Globo-H Cancer Vaccine". Accounts of Chemical Research. 48 (3): 643–652. doi:10.1021/ar5004187. ISSN 0001-4842. PMID 25665650.
  13. ^ Rugo, Hope S.; Chow, Louis W. C.; Cortes, Javier; Fasching, Peter A.; Hsu, Pei; Huang, Chiun-Sheng; Kim, Sung-Bae; Lu, Yen-Shen; Melisko, Michelle E.; Nanda, Rita; Sharma, Priyanka (2020-05-20). "Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence". Journal of Clinical Oncology. 38 (15): TPS599. doi:10.1200/jco.2020.38.15_suppl.tps599. ISSN 0732-183X. S2CID 219778189.
  14. ^ Zhou, Zhifang; Liao, Guochao; Mandal, Satadru S.; Suryawanshi, Sharad; Guo, Zhongwu (2015). "A fully synthetic self-adjuvanting globo H-Based vaccine elicited strong T cell-mediated antitumor immunity". Chemical Science. 6 (12): 7112–7121. doi:10.1039/c5sc01402f. ISSN 2041-6520. PMC 4762603. PMID 26918109.
  15. ^ Ghosh, Samir; Trabbic, Kevin R.; Shi, Mengchao; Nishat, Sharmeen; Eradi, Pradheep; Kleski, Kristopher A.; Andreana, Peter R. (2020). "Chemical synthesis and immunological evaluation of entirely carbohydrate conjugate Globo H-PS A1". Chemical Science. 11 (48): 13052–13059. doi:10.1039/d0sc04595k. ISSN 2041-6520. PMC 8163331. PMID 34123241.
  16. ^ Chen, Yu-Chi; Yang, Ming-Chen; Shia, Chi-Sheng; Tsao, Chun-Yen; Lai, Jiann-Shiun; Chen, I-Ju (2019-07-01). "Abstract 4814: Specificity, biodistribution, tumor targeting, and pharmacokinetics of a novel humanized anti-Globo H antibody, OBI-888, for cancer immunotherapy". Experimental and Molecular Therapeutics. Vol. 79. American Association for Cancer Research. p. 4814. doi:10.1158/1538-7445.am2019-4814. S2CID 242693378. {{cite book}}: |journal= ignored (help)
  17. ^ Chen, Yu-Chi; Yang, Ming-Chen; Tsai, Yi-Chien; Chang, Hui-Wen; Hsieh, Chang-Lin; Chen, Yu-Jung; Lee, Kuang-Hsiu; Lai, Jiann-Shiun; Chen, I-Ju (2019-07-01). "Abstract 544: Anti-tumor efficacy and potential mechanism of action of a novel therapeutic humanized anti-Globo H antibody, OBI-888". Clinical Research (Excluding Clinical Trials). Vol. 79. American Association for Cancer Research. p. 544. doi:10.1158/1538-7445.am2019-544. S2CID 241616016. {{cite book}}: |journal= ignored (help)
  18. ^ OBI Pharma, Inc (2020-08-04). "A Phase I/II, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors". {{cite journal}}: Cite journal requires |journal= (help)
  19. ^ Yang, Ming-Chen; Chen, Yu-Jung; Shia, Chi-Sheng; Chang, Hui-Wen; Li, Wan-Fen; Yu, Cheng-Der Tony; Chen, I-Ju (2019-07-01). "Abstract 4815: Novel Globo H targeting antibody-drug conjugate with binding specificity and anti-tumor efficacy in multiple cancer types". Experimental and Molecular Therapeutics. Vol. 79. American Association for Cancer Research. p. 4815. doi:10.1158/1538-7445.am2019-4815. S2CID 219265652. {{cite book}}: |journal= ignored (help)
  20. ^ Tsimberidou, Apostolia Maria; Ajani, Jaffer A.; Hsu, Pei; Chen, I-Ju; Pearce, Tillman E. (2020-05-20). "A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors". Journal of Clinical Oncology. 38 (15): TPS3657. doi:10.1200/jco.2020.38.15_suppl.tps3657. ISSN 0732-183X. S2CID 219773934.
  21. ^ Inc, OBI Pharma. "OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999". www.prnewswire.com. Retrieved 2021-02-27. {{cite web}}: |last= has generic name (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Globo_H&oldid=1103146847"